IZERVAY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Izervay, and what generic alternatives are available?
Izervay is a drug marketed by Astellas and is included in one NDA. There are eight patents protecting this drug.
This drug has ninety-eight patent family members in twenty-seven countries.
The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this compound. Additional details are available on the avacincaptad pegol sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Izervay
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 14, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for IZERVAY
International Patents: | 98 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for IZERVAY |
What excipients (inactive ingredients) are in IZERVAY? | IZERVAY excipients list |
DailyMed Link: | IZERVAY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for IZERVAY
Generic Entry Date for IZERVAY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVITREAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for IZERVAY
Drug Class | Complement Inhibitor |
Mechanism of Action | Complement Inhibitors |
US Patents and Regulatory Information for IZERVAY
IZERVAY is protected by eight US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of IZERVAY is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting IZERVAY
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IZERVAY
When does loss-of-exclusivity occur for IZERVAY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06214437
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0607002
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 97889
Estimated Expiration: ⤷ Try a Trial
Patent: 97900
Estimated Expiration: ⤷ Try a Trial
Patent: 92874
Estimated Expiration: ⤷ Try a Trial
Patent: 24030
Estimated Expiration: ⤷ Try a Trial
China
Patent: 1155822
Estimated Expiration: ⤷ Try a Trial
Patent: 3352037
Estimated Expiration: ⤷ Try a Trial
Patent: 4404046
Estimated Expiration: ⤷ Try a Trial
Patent: 8148840
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering IZERVAY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2006214437 | Aptamer therapeutics useful in the treatment of complement-related disorders | ⤷ Try a Trial |
European Patent Office | 2578683 | Agents thérapeutiques à base d'aptamères utiles dans le traitement de troubles liés au complément (Aptamer therapeutics useful in the treatment of complement-related disorders) | ⤷ Try a Trial |
Canada | 2992874 | AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS) | ⤷ Try a Trial |
Australia | 2022201404 | Methods for treating or preventing ophthalmological conditions | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |